Rasio utang jangka dawa marang modal Cyclacel (BGMS)

Bio Green Med Solution Inc is currently experiencing an acute liquidity shortage due to trial costs. At the same time, the company maintains a high reputation for developing precise cell cycle inhibitors. The long-term financial dependency ratio confirms this, as the indicator stands at 0.00. However, fierce competition for oncology investments creates risks of losing funding should other players achieve success.

Investors must balance the growth potential of Bio Green Med Solution Inc (BGMS) shares against the risks of excessive debt load. This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity. The trend of long-term loans to equity on GURU.Markets reflects the issuer's current financial leverage. Low values confirm resilience to shocks, which is critical for a startup in the clinical trial phase. The strategy of Bio Green Med Solution Inc (BGMS) to attract pharma partners allows for the scaling of developments while minimizing reliance on borrowed capital.